CD101 as an indicator molecule for pathological changes at the interface of host-microbiota interactions

Area of Science:

• Immunology
• Microbiology
• Gastroenterology

Background:

• Intestinal microbiota regulate host biochemical, metabolic, and immunological processes.
• Disruptions in host-microbiota interactions contribute to immune-mediated disorders like IBD and T1D.
• Altered gut microbiota and increased intestinal permeability are hallmarks of IBD and T1D.

Purpose of the Study:

• To investigate the role of CD101 expression on immune cells in the context of IBD and T1D.
• To explore the relationship between intestinal microbiota composition and CD101 expression.
• To understand how dysbiosis impacts immune cell function in these diseases.

Main Methods:

• Analysis of CD101 expression on myeloid cells, intraepithelial lymphocytes (IELs), and regulatory T cells (Tregs).
• Assessment of immune cell profiles and cytokine production.
• Correlation of CD101 expression with intestinal microbiota composition and bacterial translocation.

Main Results:

• CD101 expression on myeloid cells and T lymphocytes confers protection against experimental enterocolitis and T1D.
• Reduced CD101 expression is observed in patients with T1D and IBD.
• Distinct bacteria and inflammation suppress CD101 expression on immune cells.

Conclusions:

• Reduced CD101 expression in T1D and IBD patients may result from gut dysbiosis and bacterial translocation.
• This reduction could contribute to heightened inflammatory immune responses in these conditions.
• Targeting host-microbiota interactions and CD101 expression may offer therapeutic strategies for IBD and T1D.